Argenx’s shares fall sharply after the company halts a late-stage Phase 3 study of its blockbuster therapy Vyvgart in patients with Sjögren’s disease. Argenx says the trial does not show Vyvgart outperforming placebo, and a monitoring board recommends stopping the study for futility.
The setback comes as investors had expected continued expansion of Vyvgart into additional autoimmune indications. Different outlets highlight the same core result—lack of efficacy in the Sjögren’s program—but describe the impact in terms of market expectations: one outlet frames it as an unexpected obstacle to a potential “blockbuster expansion” plan, while another reports the stock decline and the removal of remaining upside tied to the trial’s success.
Overall, sources agree that the Sjögren’s Phase 3 failure is an unusual clinical setback for the company’s late-stage pipeline and is driving a significant negative market reaction, even as other development efforts continue.
